Response regulator polynucleotides
AssigneeSmithKline Beecham Corporation
InventorsJohn Edward Hodgson, Nicola Gail Wallis
Life of this patent
Estimating the term…
Abstract
Novel response regulator polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polynucleotides and polypeptides for the treatment of infection, particularly bacterial infections. Antagonists against such the polypeptides of the invention and their use as a therapeutic to treat infections, particularly bacterial infections are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to the presence the nucleic acid sequences and the polypeptides of the invention in a host. Also disclosed are diagnostic assays for detecting polynucleotides encoding response regulators and for detecting the polypeptide in a host.
Claims21
An isolated, recombinant DNA comprising the sequence fully complementary to nucleotides 1 to 850 set forth in SEQ ID NO:1.
An isolated, recombinant DNA comprising the sequence fully complementary to nucleotides 58 to 759 set forth in SEQ ID NO:1.
An isolated, recombinant DNA which encodes a polypeptide comprising amino acids 1 to 233 set forth in SEQ ID NO:2.
An isolated RNA comprising an RNA sequence encoding the polypeptide sequence of SEQ ID NO:2.
An isolated RNA consisting of an RNA sequence transcribed from nucleotides 58 through 759 of SEQ ID NO:1.
An isolated polynucleotide segment, comprising a first polynucleotide sequence, wherein the first polynucleotide sequence is selected from the group consisting of:
- (a) a first sequence having the polynucleotide sequence set forth in SEQ ID NO:1;
- (b) a second sequence having nucleotides 1 to 850 of the polynucleotide sequence set forth in SEQ ID NO:1;
- (c) a third sequence having nucleotides 58 to 759 of the polynucleotide sequence set forth in SEQ ID NO:1;
- (d) a fourth sequence having at least 30 sequential bases of the polynucleotide sequence set forth in SEQ ID NO:1;
- (e) a fifth sequence having at least 50 sequential bases of the polynucleotide sequence set forth in SEQ ID NO:1;
- and
- (f) the frill complement of the entire length of the polynucleotide sequence of (a), (b), (c), (d) or (e).
An isolated polynucleotide segment, comprising a first polynucleotide sequence, wherein the first polynucleotide sequence encodes a polypeptide sequence selected from the group consisting of:
- (a) the sequence set forth in SEQ ID NO:2;
- (b) a portion of SEQ ID NO:2 containing at least 30 amino acids;
- and
- (c) a portion of SEQ ID NO:2 containing at least 50 atino acids;
- wherein the polypeptide sequence is capable of generating antibodies having binding specificity for the amino acid sequence set forth in SEQ ID NO:2.
Dependencies are inferred from the claim text.